Alpex Acquisition Corp.
ALPX
NASDAQ9.86
USD
- -
- -
CIK
0002125551
ISIN
KYG633251072
CUSIP
G63325123
Return %
Stock
S&P500
1Y
0.20
18.21
3Y
0.20
64.38
5Y
0.20
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiaolin Zheng
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 300 Delaware Ave. Suite 210 #494 Wilmington DE United States of America 19801
- IPO Date
- Jul 7, 2026
- CIK
- 0002125551
- Similar Companies
- Business
- Alopexx, Inc. (ALPX) is a clinical-stage biotechnology company that develops novel, broad-spectrum immune therapeutics targeting poly N-acetyl glucosamine (PNAG), a conserved surface polysaccharide found on over 75 bacterial, fungal, and parasitic pathogens, for the prevention, treatment, and mitigation of microbial infections without reliance on antibiotics. The company offers a synthetic vaccine candidate, AV0328, which has completed a Phase I trial demonstrating safety, tolerability, and induction of protective antibodies against PNAG-expressing pathogens including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases; and F598, a fully human monoclonal antibody that provides 2-3 months of protection against Gram-negative, Gram-positive bacterial, and fungal infections following a single infusion, with favorable safety profiles from Phase I and pilot Phase II trials. These therapeutics also hold potential applications beyond infectious diseases, such as neurological conditions and cognitive decline due to inflammation. Founded in 2006 and headquartered in Cambridge, Massachusetts, Alopexx operates primarily in the United States with a focus on global markets, particularly low- and middle-income countries for affordable solutions like AV0328, which costs about $1 per dose to manufacture. Recent developments include a September 2024 investment from Biotech Consortia, Inc. to advance AV0328 and other clinical programs; a September 2024 collaboration with Bharat Biotech for development and commercialization of AV0328 in India and other low- and lower-middle-income countries, featuring upfront payments, milestones, and royalties; and an ongoing initial public offering on Nasdaq targeting $12 million in proceeds as of early 2025 amendments.
Alpex Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares, Warrants and Rights, Commencing on July 7, 2026
Alpex Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares, Warrants and Rights, Commencing on July 7, 2026
Alpex Acquisition Corporation Announces Closing of $115,000,000 Initial Public Offering, Including Full Exercise of Over-allotment Option
ALPEX ACQUISITION CORPORATION ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING
Will Alopexx (ALPX) Stock Be the Next Hot IPO?
Alopexx To Raise ~$15m IPO With Ambition To Drive Blockbuster Sales As Prevnar's Partner